Biohaven (BHVN) Stock Price, News & Analysis

Company Overview

Biohaven Ltd. (NYSE: BHVN) is a biopharmaceutical company focused on discovering, developing and commercializing therapies for neurological and immunological disorders. The company uses proprietary drug-development platforms to pursue treatments for conditions with significant unmet medical needs, including migraine, epilepsy, obsessive-compulsive disorder and other central nervous system diseases.

Biohaven’s pipeline has included small-molecule and biologic candidates such as troriluzole, an investigational therapy being studied in several neurological disorders, and other programs targeting ion channels, glutamate signaling and immune pathways. Its research programs span both clinical-stage and earlier-stage candidates, although the status and indications of individual programs may change as development progresses.

The company was originally known as Biohaven Pharmaceutical Holding Company and developed the migraine medicines Nurtec ODT and Zavzpret. Pfizer acquired Biohaven’s commercial CGRP migraine portfolio in 2022, while the current Biohaven Ltd. retained and continued developing a separate pipeline of investigational medicines. Biohaven is headquartered in New Haven, Connecticut, and its operations and clinical-development activities serve patients and research markets internationally. Vlad Coric has served as the company’s chief executive officer.

Key Stats

• Today's Range: $12.63 to $13.51
• 50-Day Range: $12.03 to $17.12
• 52-Week Range: $7.48 to $18.57
• Volume: 1.74 million shs
• Average Volume: 2.89 million shs
• Market Capitalization: $1.95 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $18.69
• Consensus Rating: Moderate Buy

Biohaven Stock Analysis - MarketRank™

Biohaven scored higher than 49% of companies evaluated by MarketBeat, and ranked 511th out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Biohaven has received a consensus rating of Moderate Buy. The company's average rating score is 2.59, and is based on 2 strong buy ratings, 8 buy ratings, 5 hold ratings, and 2 sell ratings.

Upside Potential

Biohaven has a consensus price target of $18.69, representing about 45.1% upside from its current price of $12.88.

Amount of Analyst Coverage

Biohaven has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Biohaven are expected to grow in the coming year, from ($3.33) to ($2.64) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Biohaven is -2.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Biohaven is -2.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Biohaven has a P/B Ratio of 33.02. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

15.71% of the float of Biohaven has been sold short.

Short Interest Ratio / Days to Cover

Biohaven has a short interest ratio ("days to cover") of 6.52.

Change versus previous month

Short interest in Biohaven has recently increased by 7.63%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Biohaven does not currently pay a dividend.

Dividend Growth

Biohaven does not have a long track record of dividend growth.

News and Social Media

• Score: 1.3 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Biohaven this week, compared to 4 articles on an average week.

Search Interest

6 people have searched for BHVN on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

MarketBeat Follows

1 people have added Biohaven to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Biohaven insiders have not sold or bought any company stock.

Percentage Held by Insiders

13.80% of the stock of Biohaven is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

88.78% of the stock of Biohaven is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/10/2026
• Today: 10/04/2026
• Next Earnings (Estimated): 11/09/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NYSE:BHVN
• Previous Symbol: NASDAQ:BHVN
• CIK: 1935979
• Web: www.biohaven.com
• Phone: 203-404-0410
• Fax: N/A
• Employees: 274
• Year Founded: 2014

Price Target and Rating

• Average Price Target for Biohaven: $18.69
• High Price Target: $42.00
• Low Price Target: $9.00
• Potential Upside/Downside: +45.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.59
• Research Coverage: 17 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.64)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$738.82 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -1,328.94%
• Return on Assets: -138.27%

Debt

• Debt-to-Equity Ratio: 21.23
• Current Ratio: 4.73
• Quick Ratio: 4.73

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.39 per share
• Price / Book: 33.02

Miscellaneous

• Outstanding Shares: 151,040,000
• Free Float: 130,200,000
• Market Cap: $1.95 billion
• Optionable: Optionable
• Beta: 1.35